Smith Group Asset Management’s Pacira BioSciences PCRX Stock Holding History

Smith Group Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,251	Closed	-$207K	–	161
2024 Q2	$207K	Buy	7,251 +42	+0.6%	+$1.2K	0.02%	132
2024 Q1	$211K	Buy	+7,209	New	+$221K	0.01%	176
2022 Q1	$390K	Sell	5,107 -3,767	-42%	-$251K	0.02%	122
2021 Q4	$534K	Sell	8,874 -226	-2%	-$12.5K	0.02%	144
2021 Q3	$510K	Sell	9,100 -135	-1%	-$7.78K	0.03%	137
2021 Q2	$560K	Sell	9,235 -89	-1%	-$5.63K	0.03%	126
2021 Q1	$654K	Hold	9,324	–	–	0.03%	108
2020 Q4	$558K	Sell	9,324 -3,040	-25%	-$178K	0.03%	125
2020 Q3	$743K	Sell	12,364 -1,958	-14%	-$114K	0.04%	112
2020 Q2	$751K	Sell	14,322 -49	-0.3%	-$2.05K	0.04%	112
2020 Q1	$482K	Hold	14,371	–	–	0.03%	123
2019 Q4	$651K	Sell	14,371 -8,580	-37%	-$364K	0.03%	127
2019 Q3	$874K	Sell	22,951 -4,180	-15%	-$167K	0.03%	121
2019 Q2	$1.18M	Buy	27,131 +17,481	+181%	+$742K	0.04%	115
2019 Q1	$367K	Sell	9,650 -31,240	-76%	-$1.22M	0.01%	185
2018 Q4	$1.76M	Buy	+40,890	New	+$1.91M	0.06%	142

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Smith Group Asset Management's PCRX Position: Q3 2024 in Review

Smith Group Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 7,251 shares — an estimated $207K sold.

Smith Group Asset Management first reported a position in PCRX in Q4 2018 and held it in 16 quarters. The position peaked at $1.76M in Q4 2018. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Smith Group Asset Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Smith Group Asset Management sold 7,251 Pacira BioSciences shares in Q3 2024, an estimated $207K.
Smith Group Asset Management first reported a position in Pacira BioSciences in Q4 2018 and held it in 16 quarters.
Smith Group Asset Management's Pacira BioSciences position peaked at $1.76M in Q4 2018.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Smith Group Asset Management's 13F filing for Q3 2024, filed 25 Oct 2024.